Search
praliciguat
Not yet FDA-approved
Contraindications:
- of no benifit for treatment of left ventricular diastolic dysfunction [1]
Mechanism of action:
- stimulates activation of guanylate cyclase
General
soluble guanylate cyclase stimulator
Database Correlations
PUBCHEM cid=86269973
References
- Udelson JE et al.
Effect of praliciguat on peak rate of oxygen consumption in patients
with heart failure with preserved ejection fraction: The CAPACITY HFpEF
randomized clinical trial.
JAMA 2020 Oct 20; 324:1522.
PMID: 33079154
https://jamanetwork.com/journals/jama/article-abstract/2771902